Research Progress in Effects of MicroRNA15a and MicroRNA16 on Fibrotic Diseases

Overview

Journal Zhong Nan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2023 Aug 4

PMID 37539577

Authors

Dada Wen

Jie Wang

Affiliations

Soon will be listed here.

Abstract

MicroRNA (miR) is a class of highly conserved non-coding single-stranded RNA widely existing in mammals, which can negatively regulate the expression of targeting genes after transcription. As a key regulator, miR negatively regulates the expression of the targeting genes and disrupts important molecular signaling pathways, leading to the imbalance of multiple pathways such as tissue repair and inflammation involved in the fibrotic process. Among them, miR-15a/16 can participate in regulating and controlling the fibrotic process of various organs, including liver, lung, heart, kidney and other fibrotic diseases by acting on cell proliferation and transformation, extracellular matrix proteins production and degradation, inflammation and other important cell functions. It has potential diagnostic and therapeutic value. Clarifying the biological function of miR-15a/16 and its mechanism for action and therapeutic application prospects in various fibrotic lesions are of great significance for the molecular targeted treatment of fibrotic diseases.

References

Arakeri G, Rai K, Hunasgi S, Merkx M, Gao S, Brennan P . Oral submucous fibrosis: An update on current theories of pathogenesis. J Oral Pathol Med. 2017; 46(6):406-412. DOI: 10.1111/jop.12581. View

Hullinger T, Montgomery R, Seto A, Dickinson B, Semus H, Lynch J . Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2011; 110(1):71-81. PMC: 3354618. DOI: 10.1161/CIRCRESAHA.111.244442. View

Xie T, Liang J, Guo R, Liu N, Noble P, Jiang D . Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation. Physiol Genomics. 2011; 43(9):479-87. PMC: 3110895. DOI: 10.1152/physiolgenomics.00222.2010. View

Bo Y, Liu B, Yang L, Zhang L, Yan Y . Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis. Biochem Biophys Res Commun. 2021; 561:113-119. DOI: 10.1016/j.bbrc.2021.05.046. View

Piccoli M, Gupta S, Viereck J, Foinquinos A, Samolovac S, Kramer F . Inhibition of the Cardiac Fibroblast-Enriched lncRNA Prevents Cardiac Fibrosis and Diastolic Dysfunction. Circ Res. 2017; 121(5):575-583. DOI: 10.1161/CIRCRESAHA.117.310624. View

Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L . Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol. 2011; 225(3):364-77. PMC: 3258545. DOI: 10.1002/path.2961. View

Qi H, Cao Q, Liu Q . MicroRNA-16 directly binds to DEC2 and inactivates the TLR4 signaling pathway to inhibit lupus nephritis-induced kidney tissue hyperplasia and mesangial cell proliferation. Int Immunopharmacol. 2020; 88:106859. DOI: 10.1016/j.intimp.2020.106859. View

Yang Y, Yang F, Yu X, Wang B, Yang Y, Zhou X . miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury. Biomed Pharmacother. 2019; 112:108664. DOI: 10.1016/j.biopha.2019.108664. View

Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D . DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 2009; 315(17):2941-52. DOI: 10.1016/j.yexcr.2009.07.001. View

10.

Huang E, Liu R, Chu Y . miRNA-15a/16: as tumor suppressors and more. Future Oncol. 2015; 11(16):2351-63. DOI: 10.2217/fon.15.101. View

11.

Dolcino M, Pelosi A, Fiore P, Patuzzo G, Tinazzi E, Lunardi C . Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures. Front Immunol. 2018; 9:449. PMC: 5845728. DOI: 10.3389/fimmu.2018.00449. View

12.

Tao R, Fan X, Yu H, Ai G, Zhang H, Kong H . MicroRNA-29b-3p prevents Schistosoma japonicum-induced liver fibrosis by targeting COL1A1 and COL3A1. J Cell Biochem. 2017; 119(4):3199-3209. DOI: 10.1002/jcb.26475. View

13.

Inomata M, Kamio K, Azuma A, Matsuda K, Usuki J, Morinaga A . Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis. Exp Cell Res. 2020; 398(2):112416. DOI: 10.1016/j.yexcr.2020.112416. View

14.

Thakral S, Ghoshal K . miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2014; 15(2):142-50. PMC: 4439190. DOI: 10.2174/1566523214666141224095610. View

15.

Lacedonia D, Scioscia G, Soccio P, Conese M, Catucci L, Palladino G . Downregulation of exosomal let-7d and miR-16 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2021; 21(1):188. PMC: 8176704. DOI: 10.1186/s12890-021-01550-2. View

16.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

17.

Liu X, Pan Q, Zhang R, Shen F, Yan S, Sun C . Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016; 22(44):9844-9852. PMC: 5124990. DOI: 10.3748/wjg.v22.i44.9844. View

18.

Gao Y, Yu Z . MicroRNA‑16 inhibits interleukin‑13‑induced inflammatory cytokine secretion and mucus production in nasal epithelial cells by suppressing the IκB kinase β/nuclear factor‑κB pathway. Mol Med Rep. 2018; 18(4):4042-4050. DOI: 10.3892/mmr.2018.9394. View

19.

Catela Ivkovic T, Voss G, Cornella H, Ceder Y . microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett. 2017; 407:113-122. DOI: 10.1016/j.canlet.2017.04.007. View

20.

Kasar S, Underbayev C, Yuan Y, Hanlon M, Aly S, Khan H . Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene. 2013; 33(25):3307-15. PMC: 4508006. DOI: 10.1038/onc.2013.291. View